<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01754350</url>
  </required_header>
  <id_info>
    <org_study_id>ERGO2</org_study_id>
    <nct_id>NCT01754350</nct_id>
  </id_info>
  <brief_title>Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma</brief_title>
  <acronym>ERGO2</acronym>
  <official_title>Calorie-restricted, Ketogenic Diet and Transient Fasting vs. Standard Nutrition During Reirradiation for Patients With Recurrent Glioblastoma: the ERGO2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TAVARLIN (Darmstadt, Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased glucose metabolism is characteristic for solid tumors. Thereby, glucose is
      important for the generation of ATP, supply of anabolic substrates and defense against
      reactive oxygen species in tumor cells. In preclinical models, restricting glucose
      availability using a ketogenic diet, calorie-restriction or transient fasting inhibits tumor
      growth.

      Therefore, the purpose of the study is to evaluate whether a calorie-restricted, ketogenic
      diet and transient fasting can enhance the efficacy of reirradiation in patients with
      recurrent glioblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free-survival</measure>
    <time_frame>6 months</time_frame>
    <description>Progression-free-survival rates 6 months after reirradiation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>feasibility measured as median number on diet per patient and average calorie and carbohydrate intake per day during day 1-9</measure>
    <time_frame>day 1-12</time_frame>
    <description>Feasibility of the calorie-restricted, ketogenic diet and the transient fasting measured as median number on diet per patient and average calorie and carbohydrate intake per day during day 1-9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as defined as number of patients with adverse events</measure>
    <time_frame>day 1-12</time_frame>
    <description>Safety and tolerability of the calorie-restricted, ketogenic diet and the transient fasting as defined as number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free-survival</measure>
    <time_frame>1 month, 3 months</time_frame>
    <description>progression-free-survival rates 1 month and 3 month after reirradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>overall survival after the reirradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of seizures</measure>
    <time_frame>day 1-12</time_frame>
    <description>frequency of seizures at day 1-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ketosis</measure>
    <time_frame>day 1-12</time_frame>
    <description>urine and blood ketosis and metabolic parameters (glucose, insulin, IGF-1) during day 1-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the EORTC Quality of Life Questionnaire</measure>
    <time_frame>day 1-12</time_frame>
    <description>Quality of life at day 1-12 as measured by the EORTC Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depression</measure>
    <time_frame>day 1-12</time_frame>
    <description>depression as measured by SCL-90 at day 1-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>attention</measure>
    <time_frame>day 1-12</time_frame>
    <description>attention as measured by d2-testing at day 1-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response</measure>
    <time_frame>1 month</time_frame>
    <description>response assessment 1 month after reirradiation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>ketogenic diet and transient fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calorie-restricted, ketogenic diet and transient fasting during reirradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard nutrition</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nutrition according to recommendations of the German society for nutrition during reirradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calorie-restricted ketogenic diet and transient fasting</intervention_name>
    <description>On day 1-3 and day 7-9, restriction of carbohydrates to &lt; 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by &quot;Tavarlin&quot;.</description>
    <arm_group_label>ketogenic diet and transient fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>standard nutrition</intervention_name>
    <description>nutrition as recommended by the german society for nutrition, 30 kcal/kg per day</description>
    <arm_group_label>standard nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;= 18 years

          -  recurrence of a histologically confirmed glioblastoma or gliosarcoma

          -  at least 6 months after first surgery

          -  at least 6 months after first radiotherapy

          -  interdisciplinary recommendation for reirradiation

          -  karnofsky performance status &gt;= 60, ECOG &lt;= 2

          -  creatinine &lt;= 2,0 mg/dl, urea &lt;= 100 mg/dl

          -  ALAT, ASAT &lt;= 7x upper normal limit

        Exclusion Criteria:

          -  bowel obstruction, subileus

          -  insulin-dependent diabetes

          -  decompensated heart failure (NYHA &gt; 2)

          -  myocardial infarction within the last 6 months, symptomatic atrial fibrillation

          -  severe acute infection

          -  malnutrition, cachexia

          -  other medical conditions that might increase the risk of the dietary intervention

          -  pregnancy

          -  uncontrolled thyroid function

          -  pancreatic insufficiency

          -  dementia or other clinically relevant alterations of the mental status which could
             impair the ability of the patient to apply to the diet or understand the informed
             consent of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Senckenberg Institute of Neurooncology</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Johannes Rieger</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>ketogenic diet</keyword>
  <keyword>glioma</keyword>
  <keyword>fasting</keyword>
  <keyword>reirradiation</keyword>
  <keyword>nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

